SOPHiA GENETICS (NASDAQ: SOPH) and MSK plan precision oncology hub MOU
Filing Impact
Filing Sentiment
Form Type
6-K
Rhea-AI Filing Summary
SOPHiA GENETICS filed a Form 6-K highlighting a new Memorandum of Understanding with Memorial Sloan Kettering Cancer Center to work toward forming a joint venture focused on precision oncology. The envisioned precision medicine hub would combine MSK’s extensive clinical data and expertise with SOPHiA GENETICS’s Ai-driven SOPHiA DDM™ platform.
The collaboration aims to discover, develop, and deploy next-generation precision oncology solutions for patients worldwide and create infrastructure for biopharma companion diagnostics and clinical algorithms. The agreement is currently an MOU, and detailed terms of the strategic initiative have not yet been finalized.
Positive
- None.
Negative
- None.
Insights
SOPHiA GENETICS and MSK sign an MOU for a potential precision oncology joint venture, highlighting strategic but still early-stage collaboration.
SOPHiA GENETICS and Memorial Sloan Kettering Cancer Center signed a Memorandum of Understanding to explore a joint venture around a precision medicine hub. The hub would pair MSK’s large, outcomes-linked genomic dataset with the SOPHiA DDM™ Ai and analytics platform.
The initiative targets multimodal precision oncology and services for biopharma, including companion diagnostics and clinical algorithm development. However, the press release notes that specifics of the strategic initiative have yet to be finalized, so operational scope, economics, and timing are not defined in this disclosure.
The companies already collaborate via licensed MSK assays deployed on SOPHiA DDM™ in 35 countries, suggesting an established working relationship. Future company filings may clarify definitive joint venture agreements, governance, and any financial commitments once negotiations advance beyond the current MOU stage.
Key Figures
Cases analyzed on SOPHiA DDM: more than 2.5 million cases
MSK tumor samples sequenced: more than 150,000 tumor samples
Countries with MSK assays via SOPHiA DDM: 35 countries
3 metrics
Cases analyzed on SOPHiA DDM
more than 2.5 million cases
since 2014 on SOPHiA GENETICS's precision medicine platform
MSK tumor samples sequenced
more than 150,000 tumor samples
MSK in-house NGS program since 2014
Countries with MSK assays via SOPHiA DDM
35 countries
MSK-IMPACT and MSK-ACCESS deployed using SOPHiA DDM™
Key Terms
Memorandum of Understanding, joint venture, precision oncology, companion diagnostics, +1 more
5 terms
Memorandum of Understanding regulatory
"announced that the company has signed a Memorandum of Understanding (MOU) with Memorial Sloan Kettering"
A memorandum of understanding (MOU) is a formal agreement between two or more parties that outlines their shared intentions and plans to work together. It acts like a handshake in writing, clarifying each side’s roles and expectations before any official contract is signed. For investors, an MOU signals that parties are serious about collaboration, which can influence future business opportunities and potential growth.
joint venture financial
"relating to the formation of a joint venture between the two institutions"
A joint venture is when two or more companies team up to work on a specific project or business idea, sharing both the risks and the rewards. It’s like friends starting a lemonade stand together—each contributes resources and they split the profits, making it easier to succeed than going alone.
precision oncology medical
"a new generation of precision oncology to patients around the world"
Precision oncology uses detailed biological information from a patient’s tumor—like genetic changes or specific markers—to choose treatments most likely to work for that individual, much like tailoring a suit to a person’s measurements instead of selling one-size-fits-all clothing. It matters to investors because these targeted approaches can improve treatment success, support premium pricing and companion diagnostic tests, and shorten development and approval timelines, creating focused markets with both higher potential returns and specialized risks.
companion diagnostics medical
"infrastructure for next-generation companion diagnostics, clinical algorithm development, and evidence generation"
A companion diagnostic is a medical test used alongside a specific drug or therapy to identify which patients are likely to benefit from it or may face safety risks. Think of it as a tailored matchmaker that tells doctors whether a particular treatment is a good fit for an individual. For investors, these tests matter because they can shape a drug’s approved use, speed and cost of development, patient uptake, reimbursement, and the commercial value of both the therapy and the diagnostic.
Ai-enabled precision medicine technical
"as interest in Ai-enabled precision medicine continues to grow"
AI-enabled precision medicine uses computer intelligence to analyze a patient’s biological, lifestyle and medical data to choose or design treatments that are more likely to work for that individual. For investors it signals potential for smaller, faster clinical trials, lower development costs and therapies that can command premium prices or capture niche markets — think of it as using smart maps to find the fastest route to an effective treatment.
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 6-K
REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934
For the month of June 2026.
____________________________________
Commission File Number: 001-40627
SOPHiA GENETICS SA
(Exact name of registrant as specified in its charter)
La Pièce 12
CH-1180 Rolle
Switzerland
(Address of principal executive office)
Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F:
Form 20-F | ☒ | Form 40-F | ||||||||||||
SIGNATURE
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.
| SOPHiA GENETICS SA | ||||||||
Date: June 4, 2026 | ||||||||
| By: | /s/ Daan van Well | |||||||
| Name: | Daan van Well | |||||||
| Title: | Chief Legal & Regulatory Officer | |||||||
EXHIBIT INDEX
| Exhibit No. | Description | ||||
99.1 | Press Release dated June 4, 2026 | ||||
SOPHiA GENETICS Signs Strategic Collaboration MOU with Leading Global Cancer Center SOPHiA GENETICS and Memorial Sloan Kettering Cancer Center Aim to Establish Precision Medicine Hub for the Next Generation of Precision Oncology NEW YORK – June 4, 2026 – SOPHiA GENETICS (NASDAQ: SOPH) today announced that the company has signed a Memorandum of Understanding (MOU) with Memorial Sloan Kettering Cancer Center (MSK) relating to the formation of a joint venture between the two institutions. The joint venture aims to build upon the strength of MSK innovation in clinical diagnostics and SOPHiA GENETICS’s Ai platform to potentially discover, develop, and deploy a new generation of precision oncology to patients around the world. SOPHiA GENETICS and MSK bring unique strengths to the collaboration. SOPHiA DDM™, SOPHiA GENETICS's precision medicine platform, has been used to analyze more than 2.5 million cases since 2014, pioneering a unique, decentralized approach to precision oncology. MSK's in-house NGS program has sequenced more than 150,000 tumor samples since 2014, creating an extensive genomic dataset linked to clinical outcomes, pathology, and radiology records. The MOU envisions a precision medicine hub that would combine MSK's clinical data and expertise with SOPHiA GENETICS’s Ai platform to unlock a new approach to multimodal precision oncology. For patients, the proposed precision medicine hub will act as an incubation studio for the discoveries of tomorrow, equipped with a deployment platform to quickly deliver new capabilities to patients worldwide. The hub could move new discoveries from bench to clinical care faster than traditional models, expanding access to MSK’s oncology intelligence for patients across the globe. For biopharma partners, the hub could provide dedicated infrastructure for next-generation companion diagnostics, clinical algorithm development, and evidence generation. The two institutions have a history of successful collaboration. Through previous license agreements involving MSK assays such as MSK-IMPACT and MSK-ACCESS, SOPHiA GENETICS has brought MSK diagnostics innovation to hospitals, labs, and patients in 35 countries across the globe using its platform SOPHiA DDMTM. Although the specifics of this strategic initiative have yet to be finalized, it is envisioned that SOPHiA DDM™ would serve as the Ai and analytics platform of the precision medicine hub, supporting its data, Ai, and bioinformatics needs. MSK would contribute its clinical and scientific leadership, including support from its oncology faculty and exceptional ability to generate high-quality clinical data. SOPHiA GENETICS’s announcement of this Memorandum of Understanding comes at a pivotal moment in oncology, as interest in Ai-enabled precision medicine continues to grow. New targeted cancer therapies are pushing molecular diagnostics earlier in the treatment pathway, creating demand for new diagnostic capabilities and scalable testing platforms. At the same time, Ai is emerging as a critical tool for clinical decision-making, making the combination of clinical data and Ai infrastructure one of the field's most strategic capabilities. Ross Muken, President, SOPHiA GENETICS, said: "Our work with MSK has always been about extending the reach of MSK’s clinical intelligence, and this joint venture is the most ambitious expression of that mission yet. Over the past several years, we’ve built SOPHiA DDM™ into a foundational Ai and analytics layer for precision medicine, helping institutions across the world unlock the value of their clinical data. By combining MSK's clinical leadership and deep clinical data with SOPHiA GENETICS's Ai platform
and global infrastructure, the precision medicine hub that we are discussing will help move precision oncology into the multimodal era and bring the benefits of MSK’s precision oncology to patients regardless of where they're treated.” Michael G. Frank, Director of Digital Health Business Development at MSK, said: "This collaboration represents the future of applied precision oncology – where clinical expertise meets cutting-edge Ai and robotics with the potential to transform cancer care at scale. By combining MSK's deep clinical assets with SOPHiA GENETICS's powerful digital platform, we're seeking to create a new paradigm to deliver personalized insights to patients.” # # # About SOPHiA GENETICS SOPHiA GENETICS (Nasdaq: SOPH) is a cloud-native healthcare technology company on a mission to expand access to data-driven medicine by using Ai to support hospitals, laboratory, and biopharma institutions serving patients with cancer and rare disorders across the globe. It is the creator of the SOPHiA DDM™ Platform, which analyzes complex genomic and multimodal data and generates real-time, actionable insights for a broad global network of hospital, laboratory, and biopharma institutions. For more information, visit SOPHiAGENETICS.COM and connect with us on LinkedIn. SOPHiA GENETICS products are for Research Use Only and not for use in diagnostic procedures unless specified otherwise. The information in this press release is about products that may or may not be available in different countries and, if applicable, may or may not have received approval or market clearance by a governmental regulatory body for different indications for use. Please contact support@sophiagenetics.com to obtain the appropriate product information for your country of residence. SOPHiA GENETICS Forward-Looking Statements: This press release contains statements that constitute forward-looking statements. All statements other than statements of historical facts contained in this press release, including statements regarding our future results of operations and financial position, business strategy, products, and technology, as well as plans and objectives of management for future operations, are forward-looking statements. Forward-looking statements are based on our management’s beliefs and assumptions and on information currently available to our management. Such statements are subject to risks and uncertainties, and actual results may differ materially from those expressed or implied in the forward-looking statements due to various factors, including those described in our filings with the U.S. Securities and Exchange Commission. No assurance can be given that such future results will be achieved. Such forward-looking statements contained in this press release speak only as of the date hereof. We expressly disclaim any obligation or undertaking to update these forward-looking statements contained in this press release to reflect any change in our expectations or any change in events, conditions, or circumstances on which such statements are based, unless required to do so by applicable law. No representations or warranties (expressed or implied) are made about the accuracy of any such forward-looking statements. Media Contact: media@sophiagenetics.com
FAQ
What did SOPHiA GENETICS (SOPH) announce in its June 2026 Form 6-K?
SOPHiA GENETICS announced signing a Memorandum of Understanding with Memorial Sloan Kettering Cancer Center. The MOU relates to forming a joint venture that would create a precision medicine hub focused on next-generation, Ai-enabled precision oncology for patients and biopharma partners worldwide.
What is the goal of the SOPHiA GENETICS and MSK precision medicine hub?
The proposed hub aims to combine MSK’s clinical data and expertise with the SOPHiA DDM™ Ai platform. It is envisioned to discover, develop, and deploy new multimodal precision oncology approaches, moving discoveries from research into clinical care more quickly and extending access to MSK’s oncology intelligence globally.
Is the SOPHiA GENETICS and MSK joint venture already finalized?
No, the announcement describes a Memorandum of Understanding, and the specifics of the strategic initiative have yet to be finalized. The MOU outlines a vision for a joint venture and precision medicine hub, but definitive agreements, financial terms, and operational details are not provided in this disclosure.
How will SOPHiA DDM™ be used in the collaboration with MSK?
It is envisioned that SOPHiA DDM™ will serve as the Ai and analytics platform of the precision medicine hub. The platform would support data, Ai, and bioinformatics needs, helping analyze complex genomic and multimodal information and delivering real-time insights to institutions and partners involved in the hub.
What strengths does Memorial Sloan Kettering contribute to the SOPHiA GENETICS collaboration?
MSK brings an in-house NGS program that has sequenced more than 150,000 tumor samples since 2014. It contributes deep clinical and scientific leadership, high-quality clinical data linked to outcomes, and support from its oncology faculty to underpin the envisioned precision medicine hub.
What experience do SOPHiA GENETICS and MSK already have working together?
The organizations have prior license agreements involving MSK assays such as MSK-IMPACT and MSK-ACCESS. Through these, SOPHiA GENETICS has deployed MSK diagnostics innovation via its SOPHiA DDM™ platform to hospitals, laboratories, and patients in 35 countries, establishing a track record of collaboration.